Burlingame, CA, United States of America

Kristen Mae Hege

This inventor holds 14 USPTO granted patents and 21 published patent applications, plus 8 CIPO patents and 10 EPO patents. Top assignees: Signal Pharmaceuticals, Inc., Celgene Corporation. Active years: 2015-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kristen Mae Hege. Retrieved from https://idiyas.com/inventor/kristen-mae-hege

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 21)

% Patents Active = 92.9

CIPO Patents = 8 (Patent Applications = 3)

EPO Patents = 10 (Patent Applications = 21)

Average Co-Inventor Count = 3.0

ph-index = 6

Forward Citations = 70(Granted Patents)

Company Filing History:

12 out of 169

Signal Pharmaceuticals, Inc.

Years Active: 2015-2021

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11166950 - Treatment of cancer with TOR kinase inhibitors (2021-11-09),

2. 11096940 - Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection (2021-08-24),

3. 10391092 - Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy (2019-08-27),

4. 10183019 - Treatment of cancer with dihydropyrazino-pyrazines (2019-01-22),

5. 9980963 - Treatment of cancer with dihydropyrazino-pyrazines (2018-05-29),

6. 9937170 - Treatment of cancer with TOR kinase inhibitors (2018-04-10),

7. 9937169 - Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy (2018-04-10),

8. 9630966 - Treatment of cancer with dihydropyrazino-pyrazines (2017-04-25),

9. 9505764 - Treatment of cancer with dihydropyrazino-pyrazines (2016-11-29),

10. 9493466 - Treatment of cancer with TOR kinase inhibitors (2016-11-15),

11. 9474757 - Methods for treating cancer using TOR kinase inhibitor combination therapy (2016-10-25),

12. 9375443 - Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib (2016-06-28),

13. 9358232 - Methods for treating cancer using TOR kinase inhibitor combination therapy (2016-06-07),

14. 9119854 - Methods for treating cancer using combination therapy (2015-09-01),

Title: Kristen Mae Hege: Innovator in Cancer Treatment

Introduction

Kristen Mae Hege is a prominent inventor based in Burlingame, CA (US). She has made significant contributions to the field of cancer treatment, holding a total of 14 patents. Her innovative approaches focus on utilizing TOR kinase inhibitors to combat various forms of cancer.

Latest Patents

Among her latest patents, one addresses the treatment of cancer with TOR kinase inhibitors. This patent outlines methods for treating or preventing solid tumors, non-Hodgkin lymphoma, or multiple myeloma by administering an effective amount of a TOR kinase inhibitor to patients. Another notable patent involves the treatment of hepatocellular carcinoma characterized by hepatitis B virus infection. This patent describes methods for treating and/or preventing hepatocellular carcinoma (HCC) by administering a specific compound to patients suffering from HCC associated with HBV infection.

Career Highlights

Kristen has worked with several reputable companies throughout her career, including Signal Pharmaceuticals, Inc. and Celgene Corporation. Her work in these organizations has allowed her to develop and refine her innovative ideas in cancer treatment.

Collaborations

Some of her notable coworkers include Heather K Raymon and Rajesh Chopra. Their collaborative efforts have contributed to advancing research and development in the field of oncology.

Conclusion

Kristen Mae Hege's work exemplifies the impact of innovation in the medical field, particularly in cancer treatment. Her patents and collaborations highlight her dedication to improving patient outcomes through scientific advancements.

Profile summary based on public USPTO records.